Flupentixol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Flupentixol
- Pharmacist Assessment Report
- Flupentixol: From Schizophrenia to Retinal dystrophy with or without extraocular anomalies
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Flupentixol: From Schizophrenia to Retinal dystrophy with or without extraocular anomalies
One-Sentence Summary
Flupentixol is a thioxanthene antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications currently support this prediction. It is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, flupentixol is a thioxanthene-class antipsychotic that acts as an antagonist at dopamine receptors (D1, D2, D3 and D5). Its use in schizophrenia (and depression) is established.
No mechanistic link to inherited retinal degeneration has been identified. The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. No known pathway connects dopamine receptor antagonism to the disease-modifying biology of inherited retinal dystrophies.
Other predictions for this drug (for example Charcot-Marie-Tooth disease type 1G, congenital disorders of glycosylation, congenital brain malformations, glycine encephalopathy and several myopia subtypes) likewise have no supporting trials or literature. For the myopia subtypes, dopamine antagonism may even act against the generally protective effect of dopamine signalling. The predictions should be treated as hypotheses, not findings.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Flupentixol is marketed in India as single-ingredient products, with 20 valid registrations and none cancelled. The data compiled for this report does not include approved indication text. Representative registrations:
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 164614 | Ornarest 0.5mg/10mg Tablet | Strip of 10 tablets | Ravenbhel Pharmaceuticals Pvt Ltd |
| 200364 | Spenzo Depot 20 Injection | Vial of 1 ml injection | Intas Pharmaceuticals Ltd |
| 173582 | Placida Tablet | Strip of 10 tablets | Mankind Pharma Ltd |
| 90365 | Flucida 20mg Injection | Ampoule of 1 injection | Cubit Healthcare |
| 180791 | Penflu 40 mg Injection | Vial of 2 ml injection | Mova Pharmaceutical Pvt Ltd |
Both oral (tablet) and injectable forms are available.
Safety Considerations
Please refer to the package insert for safety information.
Pharmacology data show that flupentixol binds dopamine D1, D2, D3 and D5 receptors. Screening studies have also reported anti-SARS-CoV-2 activity for this class of cationic amphiphilic drugs, probably through phospholipidosis. This is not a clinical finding.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a TxGNN model (deep learning) score alone (Evidence Level L5), which may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials, no literature and no plausible mechanistic link between dopamine antagonism and inherited retinal dystrophy.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulatory source, which are currently missing and block safety screening
- Detailed mechanism of action data
- Preclinical or mechanistic evidence connecting flupentixol to retinal dystrophy pathology
- A systematic literature search to confirm that no supporting studies exist
- Assessment of route compatibility and a safety plan for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.